CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has received marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg™, a biosimilar of pegylated filgrastim. This marks the company’s third biosimilar approval in the UK, following Bevqolva™ in December 2024 and Zefylti™ in May 2025.
The latest approval adds to Dyrupeg’s regulatory success, as it had already secured a marketing nod from the European Commission (EC) in April 2025. Pegylated filgrastim is commonly used to reduce infection risk in cancer patients undergoing chemotherapy, and the launch of Dyrupeg™ is expected to enhance patient access to affordable biologic therapies across Europe and the UK.
In the exchange filing, the compamy shared, “CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg™, its pegylated filgrastim biosimilar version. Earlier in April 2025, Dyrupeg™ received marketing authorization in the European Union from the European Commission (EC). This is CuraTeQ’s third biosimilar to be approved by MHRA after the approval of Bevqolva™ in December 2024 and Zefylti™ in May 2025.”
With this milestone, CuraTeQ continues to strengthen its biosimilar portfolio and expand its footprint in the global biopharmaceutical market.
